Penumbra Inc
NYSE:PEN

Watchlist Manager
Penumbra Inc Logo
Penumbra Inc
NYSE:PEN
Watchlist
Price: 244.84 USD 1.81% Market Closed
Market Cap: 9.4B USD
Have any thoughts about
Penumbra Inc?
Write Note

Net Margin
Penumbra Inc

3%
Current
2%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
3%
=
Net Income
34.5m
/
Revenue
1.2B

Net Margin Across Competitors

Country US
Market Cap 9.4B USD
Net Margin
3%
Country US
Market Cap 204.9B USD
Net Margin
14%
Country US
Market Cap 195.2B USD
Net Margin
29%
Country US
Market Cap 146.7B USD
Net Margin
16%
Country US
Market Cap 132.6B USD
Net Margin
11%
Country IE
Market Cap 110.6B USD
Net Margin
12%
Country US
Market Cap 64.7B USD
Net Margin
9%
Country DE
Market Cap 55.6B EUR
Net Margin
8%
Country CN
Market Cap 319.2B CNY
Net Margin
34%
Country US
Market Cap 41.6B USD
Net Margin
74%
Country US
Market Cap 37.7B USD
Net Margin
9%
No Stocks Found

Penumbra Inc
Glance View

Market Cap
9.4B USD
Industry
Health Care

Penumbra Inc. is revolutionizing the landscape of medical technology with its innovative solutions tailored to treat some of the most challenging conditions in neuro and peripheral vascular health. Founded in 2004, the company has swiftly positioned itself as a leader in developing devices that empower physicians to provide advanced, minimally invasive treatment options. Penumbra's flagship products, including the Penumbra System for thrombectomy and its suite of neurovascular devices, showcase its commitment to enhancing patient outcomes and streamlining procedures. With a strong focus on research and development, the company aims to address unmet medical needs, thus facilitating its growth trajectory in a market with substantial demand. As an investment opportunity, Penumbra Inc. stands out not only for its robust pipeline of innovative technologies but also for its impressive financial performance. The company has demonstrated strong revenue growth driven by increasing market adoption of its products and strategic expansions into new therapeutic areas. With healthcare's ongoing shift toward minimally invasive treatments, Penumbra is ideally positioned to capitalize on this trend, supported by a team of experienced professionals and a culture of innovation. For investors, Penumbra offers a compelling blend of growth prospects and the potential for long-term returns as it continues to redefine standards of care in the medical device industry.

PEN Intrinsic Value
106.95 USD
Overvaluation 56%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
3%
=
Net Income
34.5m
/
Revenue
1.2B
What is the Net Margin of Penumbra Inc?

Based on Penumbra Inc's most recent financial statements, the company has Net Margin of 3%.